- Home
- CSR vs NEO Comparison
CSR vs NEO Comparison
Compare CSR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- NEO
- Stock Information
- Founded
- CSR 1970
- NEO 2001
- Country
- CSR United States
- NEO United States
- Employees
- CSR N/A
- NEO N/A
- Industry
- CSR Real Estate Investment Trusts
- NEO Precision Instruments
- Sector
- CSR Real Estate
- NEO Health Care
- Exchange
- CSR Nasdaq
- NEO Nasdaq
- Market Cap
- CSR 1.0B
- NEO 965.2M
- IPO Year
- CSR N/A
- NEO 1999
- Fundamental
- Price
- CSR $60.58
- NEO $7.22
- Analyst Decision
- CSR Buy
- NEO Buy
- Analyst Count
- CSR 8
- NEO 9
- Target Price
- CSR $72.13
- NEO $13.31
- AVG Volume (30 Days)
- CSR 107.0K
- NEO 2.2M
- Earning Date
- CSR 07-28-2025
- NEO 07-28-2025
- Dividend Yield
- CSR 5.07%
- NEO N/A
- EPS Growth
- CSR N/A
- NEO N/A
- EPS
- CSR N/A
- NEO N/A
- Revenue
- CSR $263,570,000.00
- NEO $672,361,000.00
- Revenue This Year
- CSR $4.84
- NEO $13.97
- Revenue Next Year
- CSR $3.58
- NEO $11.36
- P/E Ratio
- CSR N/A
- NEO N/A
- Revenue Growth
- CSR 2.19
- NEO 10.10
- 52 Week Low
- CSR $54.13
- NEO $6.08
- 52 Week High
- CSR $76.16
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- CSR 42.95
- NEO 44.13
- Support Level
- CSR $60.26
- NEO $6.97
- Resistance Level
- CSR $63.80
- NEO $7.40
- Average True Range (ATR)
- CSR 1.65
- NEO 0.37
- MACD
- CSR -0.39
- NEO 0.03
- Stochastic Oscillator
- CSR 18.12
- NEO 26.02
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.